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The aromatic amines 2,4-diaminotoluene (2,4-DAT) and 2,6-diaminotoluene (2,6-DAT) are
structural isomers that have been extensively studied for their mutagenic and carcinogenic
characteristics. Both compounds are rapidly absorbed after oral administration and are equally
mutagenic in the Ames test; however 2,4-DAT is a potent hepatocarcinogen, whereas 2,6-DAT
does not produce an increased incidence of tumors in rats or mice at similar doses. The Big Blue
transgenic B6C3Fj mouse carries multiple copies of the lacl mutational target gene. Our studies
were designed to determine whether the Big Blue system could be used to detect differences in
the in vivo mutagenic activity between the carcinogen-noncarcinogen pair 2,4-DAT and 2,6-DAT
and to determine whether the in vivo mutagenesis assay results correspond to the rodent
carcinogen bioassay results. Male B6C3F1 transgenic mice were exposed to 2,4-DAT or 2,6-DAT
at 0 or 1,000 ppm in the diet for 30 and 90 days or to dimethyinitrosamine as a positive control.
Mutant frequencies were nearly identical for all three groups at 30 days, while at 90 days the
mutant frequency for the hepatocarcinogen 2,4-DAT (12.1 ± 1.4x 10-5) was significantly higher
(p<0.01) as compared to both age-matched (spontaneous) controls (5.7±2.9x10-5) and the
2,6-DAT-exposed group (5.7 ± 2.4x 10-5). Results from this study demonstrate that the Big Blue
transgenic mutation assay can distinguish differences in vivo between the mutagenic responses
of hepatic carcinogens and a noncarcinogen; is sensitive to mutagens through subchronic dietary
exposure; and yields a differential response depending upon the length of time mice are exposed
to a mutagen. Environ Health Perspect 104(Suppl 3):683-686 (1996)
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Introduction
Transgenic mouse mutagenesis assays mutagenic properties ofdeleterious agents
represent a novel approach for assessing the through the use of a stable genomic inte-
mutagenicity of various compounds. gration of the X shuttle vector (XLIZ),
Before the availability of these assays, the which carries a lacItarget gene and a lacZ
mutagenic properties of chemicals were reporter gene (1,2). After treatment ofmice
often determined using only short term in with the agent in question, genomic DNA
vitro tests. The Big Blue assay represents an is isolated from the target organ(s) and the
opportunity to examine the in vivo XLIZ is recovered using in vitro phage
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packaging extracts. Infection ofEscherichia
coli SCS-8 cells followed by expression of
the lacIand lacZgenes permits the detec-
tion ofphage-carrying mutated lacIgenes.
Ifthe normal function ofthe lacIrepressor
is disrupted, the lacZ gene product, ,B-
galactosidase, is expressed resulting in the
generation of blue plaques on plates con-
taining the chromogenic substrate X-gal
(5-bromo-4-chloro-3-indolyl-,-D-galac-
topyranoside) (1). Scoring the ratio of
these blue mutant plaques to colorless non-
mutant plaques allows for the quantitative
measure of mutant frequency (MO in the
tissue ofinterest.
We examined the mutagenic response
ofthe carcinogen-noncarcinogen pair 2,4-
and 2,6-diaminotoluene (DAT) (Figure 1)
in the liver DNA ofBig Blue mice after 30
and 90 days ofexposure. Both compounds
are used extensively in the synthesis of
toluene diisocyanates for the production of
polyurethane foams and elastomers, and
the annual production of both isomers
exceeds 100 million pounds (3,4). The
compounds are equally mutagenic in the
Ames/Salmonella assay in the presence of
S9 (5), and both are readily absorbed,
metabolized, and excreted (6). However,
while the 2,4-DAT isomer was found to be
a potent rodent hepatocarcinogen when
administered at 100 and 200 ppm in the
National Toxicology Program (NTP)
bioassay (3), the 2,6-DAT isomer was not
carcinogenic when administered at doses
up to 100 ppm (4).
The Big Blue system has not been
evaluated using a wide variety ofexposure
routes. Most Big Blue studies reported to
date have used short-term, high-dose gav-
age or intraperitoneal exposures (ip) with
potent mutagens (7,8). The Big Blue assay
has been shown to be sensitive to butadiene
administered by inhalation for four weeks
(9), and there is one report in which the
Big Blue assay was used in a subchronic
CH3
H2N X
NH2
2,4-Diaminotoluene
CH3
H2N NH2
2,6-Diaminotoluene
Figure 1. Structures of 2,4-diaminotoluene and 2,6-
diaminotoluene demonstrating their close structural
similarity.
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feeding study of the potent carcinogen,
2-acetylaminofluorene (2-AAF) at 600
ppm (10). Neither of the two DAT iso-
mers examined in our study are extremely
potent in vitro mutagens; therefore, a
longer-term continuous feeding study was
chosen both to increase the sensitivity of
the assay and to more closely mimic the
dosing regimens used in the standard NTP
bioassay. We examined the lacI mutant
frequencies induced after exposing male
B6C3F1 mice to 2,4-DAT and 2,6-DAT
in feed.
Materials and Methods
Chemicals
2,4-DAT, 2,6-DAT, and dimethylnitrosa-
mine (DMN) were obtained from Aldrich
Chemical Co. (Milwaukee, WI). The
diaminotoluenes (DATs) were dissolved in
acetone before being thoroughly mixed
into ground NIH-07 feed. All chemical
and biological reagents used during DNA
isolation, packaging reactions, and plating
were supplied by Stratagene (LaJolla, CA),
with the following exceptions: NZ amine,
used in the formulation ofNZY media and
agar, was supplied by Schweizerhall Inc.
(Piscataway, NJ) and agarose was purchased
from Life Technologies (Gaithersburg,
MD). All buffers, including SM buffer, TE
buffer, 10 mM MgSO4, and dounce buffer
were made using chemicals supplied by
Sigma Chemical Co. (St. Louis, MO),
exceptwhere noted.
Animals andTreatment
Age-matched male, 6-week-old B6C3F,
transgenic mice bearing multiple copies of
the lacI gene stably inserted into their
genome (Big Blue mice) were obtained from
Stratagene (Taconic Farms, Germantown,
NY). The mice were randomly housed five
per cage and were quarantined for 7 days
before treatment was initiated. All animals
were housed in rooms maintained with
12 hour on-offlight cycles. For untreated
control and for DAT-exposed animals,
powdered NIH-07 feed containing either 0
ppm or the respective DAT at 1,000 ppm
was provided adlibitum for 30 or 90 days.
Mice were sacrificed at 31 or 91 days. Five
animals were assigned to each treatment
group. The positive control (DMN-treated)
animals received five daily ip injections of
6 mg/kg DMN in saline and were sacri-
ficed 15 days following the last injection.
All animals were sacrificed by CO2 sphyxi-
ation and cervical dislocation. Livers were
removed, immediately frozen in liquid
nitrogen, and stored at-80°C until analysis,
as described earlier (11).
DNAIsolation
Genomic DNA was isolated as described
below using theAugust 1992 version ofthe
Stratagene Big Blue Transgenic Mouse
Mutagenesis Assay Manual (12) with minor
modifications. Briefly, small liver sections
(approximately 60-80 mg) were excised
from the frozen tissue and quickly homog-
enized on ice in 3 ml dounce buffer (1.75 g
Na2HPO4, 8.0 g NaCl, 0.2 g KCl, 0.2 g
KH2PO4, 20 ml 0.5 M EDTA [ethylenedi-
amine tetraacetic acid] made up to 1 liter
at pH 8.0 prior to autoclaving). An equal
volume ofproteinase K solution (2 mg/ml
proteinase K, 2% SDS [sodium dodecyl
sulfate], 100 mM EDTA, pH 7.5) was
added to the homogenate and the mixture
was incubated in a water bath at 500C for
3 hr. After the incubation, an additional 3
ml of dounce buffer and 9 ml ofphenol:
choloroform:isoamyl alcohol (25:24:1 v/v)
(Life Technologies) was added to extract
protein. After centrifugation at 1,000xg
for 10 min, the lower organic phase and
protein at the interface were removed and
discarded using glass pipettes. This proce-
dure was repeated three times. After the
third centrifugation, the upper aqueous
phase containing the liver DNA was
removed using wide bore pipettes. The
DNA was then precipitated by the slow
addition of two volumes of ethanol. The
DNA was recovered by spooling onto a
glass rod and was resuspended in 200 to
500 pl TE buffer. The concentration of
DNA was measured spectrophotometri-
cally and adjusted to 0.5 mg/ml with TE
buffer (10 mM Tris-HCI and 1 mM
EDTA, pH 7.5, autoclaved).
PackagingGenomic DNA
Excision and packaging of the XLIZ
vector from genomic DNA was performed
using lambda phage packaging extract
(Transpack, Stratagene) according to the
Stratagene Big Blue instruction manual
(12). Rescue efficiency was estimated by
plating serial dilutions of the packaging
reactions 1 to 2 days before plating to
quantitate mutant frequency. All diluted
bacteriophages were kept at 40C and were
plated within 3 days ofpackaging.
PlatingAssay
The plating procedures generally followed
the Big Blue instruction manual (12),
with the following minor modifications.
Liquid NZY media supplemented with
0.25% maltose and 12.5 mM MgSO4 was
inoculated with an aliquot ofSCS-8 E coli
bacteria (Stratagene) from an overnight cul-
ture. After a 4-hr growth period at 370C,
the SCS-8 cells were prepared for plating
by pelleting and resuspending in 10 mM
MgSO4 at an OD600= 0.5. The efficiency
ofeach packaging reaction was determined
by plating serially diluted (1:1,000) phage
with SCS-8 E. coli in triplicate for each
sample. The number of viable plaque-
forming units (pfu) was then determined
by counting overnight plating results.
These data were then used to calculate the
volume of the original packaging reaction
necessary to yield 15,000 pfu. When plat-
ing for quantitative mutagenesis, the calcu-
lated aliquot amounting to approximately
15,000 pfu was incubated for 15 min with
2.0 ml SCS8 E. coli. The phage/bacteria
complexes were then added to 35 ml of
molten (470C) top agar (NZY media con-
taining 0.7% agarose) containing 1.5
mg/ml X-gal (Stratagene). The top agar
was then poured onto 25 x25 cm2 assay
trays containing 250 ml NZY bottom agar
and incubated overnight at 37°C. Serially
diluted phage were again plated in tripli-
cate on the second day to determine the
number ofpfu per sample. The number of
pfu per tray was never allowed to exceed
20,000 to ensure the detection offaint blue
mutant plaques, with 15,000 plaques per
plate considered to be optimum. Mutant
frequencies were calculated based on the
extrapolation from the triplicate titer plates
generated at the time ofplating for mutants
(day 2). (The number ofviable phage were
not determined by counting portions ofthe
large plates.)
Blue plaques, indicating the mutant
(lacI+) phenotype, were scored visually
using a light box and a red-cellophane
transparency to enhance the color contrast
ofthe mutant plaques. All mutant plaques
were scored by two individuals. Mutant
plaques were cored into individual tubes
containing 0.5 ml SM buffer (5.8 g NaCl,
2.0 g MgSO4 [7 H20], 50 ml 1.0 M
Tris-HCl, 5 ml 2% gelatin [w/v], made
up to 1 liter and pH 7.5 prior to autoclav-
ing) and stored at 4°C for future verifi-
cation. All mutant plaques were verified by
replating isolated phage on 100 mm2 plates
in the presence ofX-gal.
Results
Effect ofDosingTime
Two of the five positive control animals
died during treatment,. apparently due to
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the toxic effects ofDMN. All ofthe DAT-
exposed mice survived the length of the
study. The observed Mf in the livers of
DMN-treated positive control mice was
31 x 10-5, which is similar to published
values using the same treatment regimen
(8). Mutant frequencies for the untreated
control mice at 10.0 and 5.65 x 10-5 at 30
and 90 days, respectively, were similar to
those previously reported (13-15). The
increased mutant frequency observed in
2,4-DAT-treated animals was statistically
significantly different (p<0.01) from age-
matched controls after feeding the chemi-
cal for 90 days, but not following 30 days
of chemical exposure (Figure 2A and B).
These data indicate a longer dosing regi-
men may be necessary to observe induced
mutations in vivo following treatment with
less potent carcinogens. This may be due
to the cumulative effects ofchemical expo-
sure over a period of 90 days compared to
30 days, to a requirement of a longer time
period necessary for the expression of the
mutant phenotype in vivo, or a combination
ofthese and other factors.
Effects ofChemicalTreatment
The Mf (meanx 10-5± SD; n =5) at 30
days for control, 2,4-DAT, and 2,6 DAT
groups were 10.0 ± 1.9, 9.3 ± 1.4, and
8.7 ±2.8, respectively (Figure 2A). The Mf
at 90 days were 5.7± 2.9, 12.1 ± 1.4, and
5.6 ±2.4 for control, 2,4-DAT and 2,6-
DAT animals, respectively (Figure 2B).
Using a one-way analysis ofvariance with a
least significant difference test, there was a
significant difference (p<0.01) in the
observed Mf at 90 days between 2,4-DAT
treated animals as compared to either the
control or the 2,6-DAT-treated animals.
The observed increase in Mf at 90 days in
the 2,4-DAT treatment group was 2.1-fold
over the negative control group Mf at 90
days. As expected, the Mfcalculated for the
positive control DMN-treated animals was
also found to be statistically significantly
higher (3.12-fold over control) than all
other groups at both time points.
Discussion
The mutagenic isomers 2,4-DAT and 2,6-
DAT are ofspecial interest because oftheir
differing carcinogenic response in bioassays
conducted by the NTP, even though they
exhibit similar mutagenic potencies in
Salmonella typhimurium (5,6). The 2,4-
DAT isomer was shown to induce hepato-
cellular carcinoma in rats and mice in the
2-year bioassay, while 2,6-DAT did not
give rise to any tumors in male or female
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Figure 2. Mutant frequencies in male B6C3F /ac/transgenic mice following exposure to 2,4-DAT, 2,6-DAT, DMN,
or control chowfor 30 (A) or 90 (B) days. *p<0.01 when compared to untreated, age-matched control.
rats or mice at similar doses. Thus, it was
of interest to determine the in vivo muta-
genic potential ofthese isomers in the Big
Blue assay system.
In order to parallel the NTP 2-year
bioassays of 2,4-DAT and 2,6-DAT, we
chose to expose the animals to these chemi-
cal via the diet. Most Big Blue studies to
date have used short-term exposure peri-
ods, high-potency mutagens, and par-
enteral dosing regimens. We reasoned that
a continuous exposure study would also be
more relevant for comparison to NTP
bioassay results. The dose chosen (1,000
ppm) corresponds to the highest nontoxic
dose used in a 90-day subchronic study
(3,4). The results of the present study
demonstrate that 90 days was an appropri-
ate minimum time period for detecting
mutations induced by 2,4-DAT adminis-
tered by feeding. Other investigators have
used the dietary route of exposure in the
Big Blue model successfully but with the
much more potent mutagen, 2-AAF (10).
They demonstrated a 3-fold increase in Mf
over background after a 28-day subchronic
exposure to 600 ppm 2-AAF. The carcino-
gen, 2,4-DAT, at 1,000 ppm increased the
observed Mf in the liver approximately
2-fold over the Mf observed in the age-
matched control group after 90 days but
not after 30 days. The Mf in liver of the
2,6-DAT treatment group also delivered in
the diet at 1,000 ppm was not significantly,
different from the age-matched control
group after either 30 or 90 days ofchemi-
cal exposure. In this study, the positive
control mutagen DMN induced a 3-fold
increase in the observed Mf in the liver as
compared to the Mf in the age-matched
control group (Figure 2). It would appear
from these data that longer exposures to
some mutagens may be required to produce
a detectable mutagenic response in vivo.
This observation should be considered in
the design of studies assessing the in vivo
mutagenic activity ofchemicals ofweak or
unknown mutagenicity, as well as in the
critical evaluation of studies that report
negative results following short-term
chemical treatment.
In the present study, mutation frequen-
cies were assessed after 30- and 90-day
exposures to 2,4- DAT or 2,6-DAT. We
demonstrate a 2-fold increase in Mf at the
90-day time point in the 2,4-DAT-treated
animals that was significant (p< 0.01) as
compared to either the untreated controls
or the 2,6-DAT-treated animals. Both
these chemicals are in vitro mutagens in the
Ames/Salmonella assay, although only 2,4-
DAT induces unscheduled DNA synthesis
(16). That 2,4-DAT but not 2,6-DAT was
found to be mutagenic in vivo is interesting
in light of previous studies conducted in
this laboratory in which we demonstrated
that 2,4-DAT but not 2,6-DAT induces
hepatocellular proliferation (17). We pos-
tulate that a cytoproliferative effect in tar-
get organs could produce an elevated Mfin
Big Blue mice as a result of clonal expan-
sion ofchemically mutated cells. Cells car-
rying DNA damage from either 2,4-DAT
or 2,6-DAT treatment would yield muta-
tions ifforced to replicate; however, hepa-
tocellular proliferation is only induced by
2,4-DAT. The cytotoxicity and compensa-
tory cell proliferation induced by 2,4-DAT
treatment leads to mutation fixation during
cell proliferation. Such damage effectively
increases the mutation rate (mutants/cell/
generation) leading to the elevated mutant
frequency (mutants/viable phage) observed
in 2,4-DAT-exposed mice at 90 days
(Figure 2B). Such a mechanism could also
be involved in the promotion and progres-
sion stages ofcarcinogenesis (18). After 90
days of dietary exposure to 2,4-DAT, the
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Mfwas significantly elevated compared to
control (Figure 2B). This may reflect a sus-
tained proliferative stimulus that may clon-
ally expand mutant cell populations. After
a 30-day exposure period, the Mf in 2,4-
DAT-treated animals was not elevated,
suggesting that longer exposure/expression
periods may be necessary to observe the
in vivo mutagenic effects of chemicals,
the effects of chemicals administered via
dietary exposure, or both. The noncarcino-
genic isomer 2,6-DAT did not increase the
Mf in either the 30- or 90-day animals at
a treatment dose identical to the 2,4-DAT
treatment dose. Thus, 2,6-DAT may not
cause an increase in DNA damage in mouse
liver and may only show a mutagenic
response in vitro. The proliferative effect
has not been observed in 2,6-DAT-exposed
animals (17). It is conceivable that DNA
damage may have been induced in the liver
by exposure to both 2,4-DAT and 2,6-
DAT. In the absence ofcellular replication
in the case of2,6-DAT-treated mice, such
damage may have been repaired with a cor-
responding reduction of the Mf to back-
ground levels. The only known difference
between these two in vitro mutagens to
explain their widely different mutagenic
activity in vivo lies in the abiity of 2,4-
DAT to induce hepatocellular prolifera-
tion. Chemically induced cell proliferation
may therefore be a critical factor in fixation
of mutations in vivo. Consistent with a
view invoking differential DNA repair, it
has been shown recently that enhanced
repair ofDNA adducts can prevent the car-
cinogenic effects ofmethylnitrosourea (19).
In conclusion, this study demonstrates
that the Big Blue assay is able to dis-
criminate between the in vivo mutagenic
response of two compounds with differing
carcinogenic properties but with similar
mutagenic activity in S. typhimurium. The
major difference between these two chemi-
cals in vivo is an induced cell proliferative
response following exposure to 2,4-DAT
that does not occur after treatment with
2,6-DAT, suggesting an important role for
chemically induced cell proliferation on
the mutagenic effect of chemicals. This
study also illustrates that the dietary
administration ofchemicals is an appropri-
ate route of administration for in vivo
mutagenesis studies, allowing for longer
duration exposures. We believe that these
data help to validate this transgenic mouse
model as a potential indicator of carcino-
genic response and suggest that the Big
Blue assay is also useful for mechanistic
studies ofcarcinogenicity.
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